CARB-X has awarded US$6.5 to LimmaTech Bio, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases. Following the vaccination of the first participants with LBT-SA7 in a phase 1 controlled study, this fresh funding will fuel the next steps.

CARB-X 已向临床阶段的生物技术公司 LimmaTech Bio 授予 650 万美元，该公司正在开发用于预防危及生命的疾病的疫苗。在第一阶段对照研究中，第一名参与者接种 LBT-SA7 后，这笔新资金将推动下一步的发展。

LBT-SA7 is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus infections pose a significant global health challenge, causing an estimated 1 million deaths annually. Notably, 90% of all community-acquired S. aureus infections are SSTIs.

LBT-SA7旨在预防由细菌病原体金黄色葡萄球菌（S. aureus）引起的皮肤和软组织感染（SSTIs）。金黄色葡萄球菌感染构成了重大的全球健康挑战，每年导致约100万人死亡。值得注意的是，90%的社区获得性金黄色葡萄球菌感染是皮肤和软组织感染。

The absence of a vaccine to prevent S. aureus, coupled with only limited treatment options — particularly against multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA) — highlights the urgent need for effective preventive solutions..

缺乏预防金黄色葡萄球菌的疫苗，加之治疗选择有限——特别是针对多重耐药菌株（通常称为耐甲氧西林金黄色葡萄球菌（MRSA）），凸显了对有效预防解决方案的迫切需求。

LimmaTech

凌马科技

’s vaccine candidate, LBT-SA7, is the first multivalent vaccine entirely based on secreted antigens to address this critical need. LBT-SA7 contains weakened forms of the pathogen’s toxins, referred to as toxoids, designed to prevent infections by neutralizing the toxins secreted by S. aureus. This approach offers a promising solution to combat the widespread bacterial threat..

的疫苗候选物LBT-SA7是首个完全基于分泌抗原的多价疫苗，以满足这一关键需求。LBT-SA7含有病原体毒素的弱化形式，即类毒素，旨在通过中和金黄色葡萄球菌分泌的毒素来预防感染。这种方法为对抗广泛存在的细菌威胁提供了有前景的解决方案。

LimmaTech started a Phase 1 clinical trial (

LimmaTech 开始了一项 I 期临床试验 (

NCT06719219

NCT06719219

) in the U.S. after

) 在美国之后

receiving a Fast Track designation

获得快速通道指定

from the U.S. Food and Drug Administration (FDA). This first-in-human study aims to evaluate the safety and immunogenicity of LBT-SA7 against S. aureus. It is a randomized, double-blinded, and controlled dose-escalation study expected to enroll 130 healthy adults aged 18–50 years. Initial results are anticipated in the second half of 2025..

来自美国食品药品监督管理局（FDA）。这项首次人体研究旨在评估LBT-SA7针对金黄色葡萄球菌的安全性和免疫原性。这是一项随机、双盲、对照的剂量递增研究，预计招募130名18-50岁的健康成年人。初步结果预计在2025年下半年公布。

The company has obtained fresh funding from

公司已经获得了新的资金来源

CARB-X

CARB-X

to further advance the development of LBT.SA7. CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria.

为了进一步推动LBT.SA7的发展。CARB-X通过支持新抗生素和其他挽救生命的药物的研发，加速全球抗菌素创新，以对抗最危险的耐药菌。

“We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical development of our S. aureus vaccine candidate LBT-SA7 but also underscores the importance of our mission to develop efficient solutions for preventing microbial infections and protecting from their threatening consequences for affected people,” added Dr.

“我们非常感谢CARB-X的大力支持，这不仅有助于加速我们的金黄色葡萄球菌疫苗候选药物LBT-SA7的临床开发，也凸显了我们为预防微生物感染并保护受影响人群免受其威胁性后果而开发高效解决方案的使命的重要性，”博士补充道。

Franz-Werner Haas, Chief Executive Officer of LimmaTech. .

Franz-Werner Haas，LimmaTech首席执行官。

(Press release)

（新闻稿）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送